日本のジェネリック医薬品市場展望

◆英語タイトル:Japan Generics Drug Market Outlook 2020
◆商品コード:KUIK60815
◆発行会社(調査会社):KuicK Research
◆発行日:2016年4月
◆ページ数:66
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single userUSD1,500 ⇒換算¥171,000見積依頼/購入/質問フォーム
Multi UserUSD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuicK Research社の日本における正規販売代理店です。KuicK Research社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Japan is a small island nation located in East Asia and it is known for its economic prosperity. It sports one of the largest pharmaceutical markets like US and Europe due to which immense commercialization opportunities are present. Unique demographic structure and presence of advanced technology is the main reason for the growth of Japanese pharmaceutical industry. They have one of the most advanced research and development facilities across the world contributing significantly to the development of healthcare infrastructure. Japan has opened its pharmaceutical market for foreign trade leading to higher input of drugs. Their population is going in downward spiral where number of young people are lesser then geriatric population. In this way, they have high demand for therapeutic products due which their pharmaceutical market is increasing. Observation shows that Japanese pharmaceuticals market is heavily inclined towards consumption of branded drugs. Due to presence of higher technological capabilities they were able to commercialize innovative drugs. Significant investments were made in research and development segment due to which new products are being made. It promoted the utilization of branded drugs in Japanese market. Presence of universal healthcare system also allowed the patients to include generic drugs in their therapeutic regime. They to invest small out of pocket money while buying branded drugs as rest of the part is covered by the universal healthcare system. Branded drugs market got boost due to regulator’s policies but these drugs are quite costly. As a result, stagnant economy is not able to sustain burgeoning financial pressure on healthcare system.
Japanese generic drugs market is largely unchurned due to which it offers significant commercialization opportunities. Both domestic and foreign pharmaceutical companies are expected to take advantage of this scenario. Japanese regulators have developed amenable rules due to which foreign pharmaceutical companies can venture in generic drugs segment. This will increase the competition and further decrease the prices of generic drugs in Japanese market. Moreover, it will build a strong supply chain due to which dearth of generic drugs will not occur in future. Regulators will also be able to increase their consumption by promoting more numbers of patients opting for the generic drugs. In this way, they will be able to observe decrease in investments in healthcare system. To achieve higher cost savings, more work has yet to be done in coming years.
Prices of both generic and branded drugs are checked by Japanese regulators after every two years. This allows the patients to spend less money for treatment of their diseases in long-term scenario. But it could be observed that patients are not willing to switch to the generic drugs despite lesser cost. Main reason behind this fact is that cost difference between these drugs is not significant. Higher buying power of patients allow them to include costly branded drugs in their daily therapeutic regime. This scenario shows that Japanese regulators have to further decrease the prices of generic drugs in order to offer higher cost arbitrage. They also have to increase the uptake of generic drugs in order to decrease the prevalence of branded drugs as major component of healthcare system. Some of the measures have been implemented but their results are yet to be observed in coming years.
Japanese pharmaceuticals market is quite mature and still has opportunities for growth as they have lesser market shares of generic drugs. This allows significant potential to generic firms to enter in Japanese pharmaceuticals market. Presence of amenable regulation and significant efforts made to decrease healthcare spending is expected to take place in coming years. Large geriatric population plays an important role of consumers in Japanese pharmaceutical industry. They require long-term usage of drugs and switching them from branded to generic drugs will boost the market. It also offers significant commercialization opportunities as compared to other countries where generic drugs occupy major market shares. Japanese generic drugs market is expected to grow several folds in coming years, in this way, its future looks optimistic.

“Japan Generics Drug Market Outlook 2020” Report Highlights:
• Introduction to Japanese Generic Drug Market
• Attractiveness of Japanese Generic Market
• Super Generics in Japan
• Japan Healthcare System & Generic Drugs
• Different Parameters for Generic & Branded Drugs
• Comparison of Generic Drugs in US & Japan
• Japan Generics Drug Market Analysis
• Japan Generics Drug Market Future Prospects

【レポートの目次】

1. Introduction to Japan Generic Drug Market
1.1 Reasons for Growth of Japan Generic Market
1.2 Some Misconceptions Related to Generic Drugs in Japan

2. Attractiveness of Japan Generic Market
2.1 Overview of Japan Pharmaceutical Market
2.2 Features of Japan Generic Drugs Market
2.3 Generic Drug Firms in Japan
2.4 Generic Drugs Import in Japan
2.5 Economic Views about Generic Drugs

3. Scenario of Generic Drugs in Japan
3.1 Scenario for Generic Drug Discount Price in Japan
3.2 Different Categories of Pharmaceutical Patent in Japan
3.3 Promotion of Generic Drugs in Japan

4. Super Generics in Japan
4.1 Introduction to Super Generics
4.2 Advantages of Super Generics
4.3 Disadvantages of Super Generics

5. Different Parameters for Generic & Branded Drugs in Japan
5.1 Patent Protection in Japan
5.2 Effect on Japan Healthcare Spending
5.3 Japan Pharmacological Parameters for Generic Drugs
5.4 Difference in Regulatory Requirements
5.5 Utilization of Branded & Generic Drugs in Japan Market

6. Generic Active Pharmaceutical Ingredients in Japan
6.1 Generic Active Pharmaceutical Ingredient Registration
6.2 Regulation for Foreign Companies in Japan
6.3 Manufacturing Capabilities for Generic API

7. Health in Japan & Utilization of Generic Drugs
7.1 Cancer Incidences in Japan
7.2 Increasing Diabetes Incidences in Japan
7.3 Increasing Cerebrovascular Incidences in Japan
7.4 Cardiovascular Diseases Incidences in Japan
7.5 Disease Caused by Pollution in Japan

8. Healthcare System & Generic Drugs in Japan
8.1 Universal Healthcare Coverage
8.2 Price Rise Control
8.3 Quality Control of Generic Drugs
8.4 Access to Generic Market
8.5 Patents Related Issues to Generic Drugs in Japan
8.6 Factors Restricting Uptake of Generic Drugs in Japan

9. Comparison of Generic Drugs in US & Japan
9.1 Regulatory Framework for Generic Drugs
9.2 Market Penetration of Generic Drugs
9.3 Prices of Generic Drugs
9.4 Perception towards Generic Drugs

10. Japan Generic Drugs Market Analysis

11. Japan Generic Market Favorable Factors
11.1 Ageing Population
11.2 Generic Drugs Regulations
11.3 High Technological Capabilities
11.4 Increasing Disease Incidences

12. Japan Generics Market Commercialization Challenges
12.1 Japan Regulatory Environment
12.2 Attitude towards Generic Drugs
12.3 Lower uptake of Generic Drugs
12.4 Conflicting Patent Laws

13. Japan Generic Drugs Market Future Prospects

14. Competitive Landscape
14.1 Actavis
14.2 Eisai
14.3 Fuji Pharma
14.4 GlaxoSmithKline
14.5 Hospira
14.6 Meiji Seika Pharma
14.7 Nichi-Iko Pharmaceutical
14.8 Nipro Pharma
14.9 Pfizer
14.10 Sawai Pharmaceuticals
14.11 Takeda Pharmaceutical
14.12 Towa Pharmaceutical

Figure 1-1: Reasons for Growth of Japan Generic Market
Figure 1-2: Some Steps taken by Japan Regulators to Decrease Drug Prices
Figure 1-3: Some Misconceptions Related to Generic Drugs in Japan
Figure 2-1: Some Considerations while Approaching Japan Generic Market
Figure 3-1: Discount Determination of Generic Drugs in Japan
Figure 3-2: Type of Drug Price Survey in Japan
Figure 4-1: Advantages of Super Generics
Figure 4-2: Disadvantages of Super Generics
Figure 5-1: Economic Benefits of opting Generic Drugs
Figure 5-2: Regulatory Requirement for Generic Drugs in Japan
Figure 5-3: Utilization of Branded and Generic Drugs in Japan Market
Figure 6-1: Requirements for Registration of API
Figure 6-2: Regulation for Foreign Companies in Japan
Figure 6-3: Japan - Manufacturing Capabilities for Generic API
Figure 7-1: Aim of Basic Plan to Promote Cancer Control Programs
Figure 7-2: Estimated Numbers of Cancer Cases in Japan, 2015
Figure 8-1: Position of Generics in Japan Healthcare System
Figure 8-2: Patents Related Issues to Generic Drugs in Japan
Figure 10-1: Japan - Generics Drug Market (US$ & Yen), 2014-2016
Figure 10-2: Japan - Generics Drug Share in Pharmaceutical Market (%), 2014
Figure 11-1: Japan - Generic Drugs Market Drivers
Figure 12-1: Japan - Generics Market Commercialization Challenges
Figure 13-1: Japan - Generics Drug Market (US$ & Yen), 2017-2020
Figure 13-2: Japan - Generics Drug Share of Prescription Drug (%), 2018
Figure 13-3: Japan - Generics Drug Share of Prescription Drug (%), 2020
Figure 13-4: Japan - Generics Drug Share in Pharmaceutical Market (%), 2020


Table 1-1: Some Important Features of Japan
Table 3-1: Listing Period for Various Drugs in Japan
Table 5-1: Difference between Branded and Generic Drugs in Japan
Table 5-2: Regulatory Requirements for Different Drugs in Japan
Table 7-1: Estimated Numbers of Different Cancer Affecting Japan Population, 2015
Table 7-2: Estimated Numbers of Males Affected by Different Type of Cancer in Japan, 2015
Table 7-3: Estimated Numbers of Females Affected by Different Type of Cancer in Japan, 2015
Table 7-4: Issues related with Cerebrovascular Diseases
Table 7-5: Some Important Diseases caused by Pollutants in Japan
Table 9-1: Difference in Regulatory Framework between Japan & US


【レポートのキーワード】

ジェネリック医薬品、日本

★調査レポート[日本のジェネリック医薬品市場展望]販売に関する免責事項
★調査レポート[日本のジェネリック医薬品市場展望]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆